Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3β inhibitor

DOI Web Site Web Site 参考文献7件
  • Saitoh Morihisa
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Kunitomo Jun
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Kimura Eiji
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Yamano Toru
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Itoh Fumio
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.
  • Kori Masakuni
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.

書誌事項

タイトル別名
  • Enantioselective Synthesis of the Novel Chiral Sulfoxide Derivative as a Glycogen Synthase Kinase 3.BETA. Inhibitor
  • Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3 v inhibitor

この論文をさがす

抄録

Glycogen synthase kinase 3β (GSK-3β) inhibitors are expected to be attractive therapeutic agents for the treatment of Alzheimer's disease (AD). Recently we discovered sulfoxides (S)-1 as a novel GSK-3β inhibitor having in vivo efficacy. We investigated practical asymmetric preparation methods for the scale-up synthesis of (S)-1. The highly enantioselective synthesis of (S)-1 (94% ee) was achieved by titanium-mediated oxidation with D-(−)-diethyl tartrate on gram scale.

収録刊行物

参考文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ